MedTrace Logo

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

NCT03925974 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-03-12

No results posted yet for this study

Summary

This is an open-label, phase 2 study of KN026 in subjects with HER2 expressing gastric/gastroesophageal junction cancer to evaluate efficacy and safety. The subjects will receive KN026 10 mg/kg QW or 20 mg/kg Q2W or 30mg/kg Q3W until progressive disease, unacceptable toxicity or death.

Conditions

  • Gastric/Gastroesophageal Junction Cancer

Interventions

DRUG

KN026 10 mg/kg QW

10 mg/kg QW as safety run-in dosage

DRUG

KN026 20 mg/kg Q2W

20 mg/kg Q2W as target dosage

DRUG

KN026 30 mg/kg Q3W

30 mg/kg Q3W as another target dosage

Sponsors & Collaborators

  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-17
Primary Completion
2022-05-31
Completion
2022-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03925974 on ClinicalTrials.gov